Identifying T cell markers to improve cancer immunotherapy
Defining a cross-primed anti-tumor T cell signature to guide immunotherapy development
This study is looking at how certain immune cells can make cancer treatments work better, especially by using a new way to help your body’s defenses recognize and attack tumors, which could lead to more personalized and effective therapies for patients like you.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10928143 on NIH RePORTER |
What this research studies
This research investigates how specific T cell signatures can enhance the effectiveness of immunotherapies for cancer treatment. It focuses on the role of dendritic cells in presenting tumor antigens to CD8+ T cells, which are crucial for mounting an effective immune response against tumors. By developing a novel in situ vaccination approach that combines various treatments, the research aims to improve the activation of tumor-reactive T cells and their ability to fight cancer. Patients may benefit from insights that could lead to more effective immunotherapy strategies tailored to their specific tumor characteristics.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with tumors that exhibit specific immune characteristics, particularly those with CD8+ T cell involvement.
Not a fit: Patients whose tumors do not express the necessary immune markers or who have already exhausted available immunotherapy options may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective immunotherapy options for cancer patients, potentially improving their treatment outcomes.
How similar studies have performed: Previous research has shown promising results with similar immunotherapy approaches, indicating potential for success in this area.
Where this research is happening
New York, United States
- Icahn School of Medicine at Mount Sinai — New York, United States (Active)
Researchers
- Principal investigator: Lubitz, Gabrielle — Icahn School of Medicine at Mount Sinai
- Study coordinator: Lubitz, Gabrielle
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.